- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia ; volume:28 ; number:01 ; year:2007 ; pages:20-25
Indian journal of medical & paediatric oncology ; 28, Heft 01 (2007), 20-25
- Beteiligte Personen und Organisationen
-
Jacob, L. Abraham
Bapsy, PP
Babu, K. Govind
- DOI
-
10.1055/s-0041-1733199
- URN
-
urn:nbn:de:101:1-2022051210114368316837
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jacob, L. Abraham
- Bapsy, PP
- Babu, K. Govind
Ähnliche Objekte (12)
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Imatinib Mesylate in Chronic Myeloid Leukemia
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Imatinib Mesylate in Chronic Myeloid Leukemia
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Imatinib Mesylate in Chronic Myeloid Leukemia
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia